Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is a healthy postmenopausal woman less than or equal to 65 years of age with onset of menopause less than or equal to 10 years prior to prestudy visit 1~* Patient has a uterus and no history of uterine bleeding in the past 3 months~* Patient has not had a previous endometrial biopsy within the last 4 weeks~* Patient has had a normal mammogram within the last 11 months~* Patient has had a normal pap-smear within the past 3 years prior to screening~* Patient has had a normal transvaginal ultrasound of the endometrium~* Patient is willing to avoid strenuous physical activity such as strenuous or unaccustomed weight lifting, running, bicycling, etc for the duration of the study~* Patient agrees to not consume grapefruit products beginning approximately 2 weeks prior to the first dose of study drug and throughout the study~* Patient agrees to limit daily consumption of alcohol. During the study, daily alcohol consumption should not be more than 2 glasses~* Patient agrees to limit daily consumption of caffeine. During the study, daily caffeine consumption should not exceed 3 cups of coffee~* Patient is a non-smoker~Exclusion Criteria:~* Patient is mentally or legally incapacitated~* Patient has a history of any first degree relatives with breast or endometrial cancer~* Patient has a history of multiple and/or severe allergies to prescription or non-prescription drugs or food~* Patient has used any type of estrogen or progesterone preparation unless followed by appropriate wash-out periods~* Patient has had surgery, donated approximately 500 mL of blood or has participated in another investigational study within the last 4 weeks~* Patient has a history of deep vein thromboses, coronary artery disease, heart attack or stroke~* Patient is a current user of illegal drugs~* Patient has a history of hypersensitivity to estrogen products~* Patient is unable to refrain from using anti-coagulants

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 17β-estradiol 2.0 milligrams (Type: ACTIVE_COMPARATOR): Estrace 2.0 mg tablet
- 17β-estradiol 0.5 milligrams (Type: ACTIVE_COMPARATOR): Estrace 0.5 mg tablet
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).